This is one of a series of BMJ summaries of new guidelines based on the best available evidence; they highlight important recommendations for clinical practice, especially where uncertainty or controversy exists.
This article summarises the most important recent recommendations from the National Institute for Health and Care Excellence (NICE) on the diagnosis and care of people with melanoma.
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Recommendations
NICE recommendations are based on systematic reviews of the best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the guideline development group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italics in square brackets. The recommendations specifically apply to secondary and tertiary care locations, where these patients should all be managed by specialist multidisciplinary teams (MDTs), but they will also affect the management of patients with melanoma in primary care.
The staging of melanoma is detailed and complex and the full staging system is available online. 3 The brief explanations of stage given may not be precise and are there to help make the context of the recommendation clearer.
Communication and support
• To help people make decisions about their care, follow the recommendations on communication, information provision, and support in the NICE guideline on improving outcomes for people with skin tumours including melanoma. 4 
[Based on low to high quality evidence from observational studies and on the experience and opinion of the guideline development group (GDG).]
Assessing melanoma
• Assess all pigmented skin lesions that are referred for assessment or identified during follow-up using dermoscopy carried out by healthcare professionals trained in this technique. The bottom line
• Use dermoscopy to examine all pigmented lesions referred for assessment and ensure that all staff are adequately trained in its use
• Consider sentinel node biopsy as a staging tool for patients with stage II melanoma and stage 1B melanoma thicker than 1 mm. Use box 1 or the options grid being developed to discuss the potential advantages and disadvantages of the procedure with patients
• If a sentinel node biopsy is positive for melanoma, discuss the potential advantages and disadvantages of completion lymphadenectomy with the patient using box 2 or the options grid being developed
• Consider regular imaging in patients at greater risk of progression to stage IV (metastatic) melanoma. Use box 3 or the options grid being developed to discuss potential advantages and disadvantages of this with the patient How patients were involved in the creation of this article 
Managing suboptimal vitamin D levels
Many people with melanoma have suboptimal levels of vitamin D at diagnosis but are usually advised to avoid sun exposure to reduce the risk of further melanomas. Vitamin D is important for bone health and possibly for other aspects of health, so further reduction in levels should be avoided. The guideline also suggests avoiding high levels as a result of unnecessary supplementation.
• Measure vitamin D levels at diagnosis in all people with melanoma.
• For people whose vitamin D levels are thought to be suboptimal, provide advice on supplementation and monitoring in line with local policies and the NICE guideline on vitamin D.
[Based on moderate to very low quality evidence from observational studies.]
Staging investigations
The role of sentinel lymph node biopsy (SLNB) is controversial, with its routine use varying greatly across England and Wales. Not all people routinely need imaging at diagnosis:
• Do not offer imaging or SLNB to people who have stage I melanoma with a Breslow thickness of 1 mm or less.
[Based on very low to high quality evidence from observational studies and on the experience and opinion of the GDG.]
• Consider SLNB as a staging rather than a therapeutic procedure for people with stages IB-IIC melanoma with a Breslow thickness of more than 1 mm, and give these people detailed verbal and written information about the possible advantages and disadvantages (see box 1 
Managing stage III melanoma (lymph nodes or in transit spread)
There is controversy and practice variation about the management of involved lymph nodes found at SLNB, by imaging, or at clinical examination.
• Consider completion lymphadenectomy (removing residual local lymph nodes) for people whose SLNB shows micrometastases and give them detailed verbal and written information about the possible advantages and disadvantages (see box 2 People who have had SLNB may be able to take part in clinical trials of new treatments for melanoma. These trials often cannot accept people who haven't had this operation
Disadvantages
The purpose of SLNB is not to cure the cancer. There is no good evidence that people who have the operation live longer than those who do not have it
The result needs to be interpreted with caution. For every 100 people with a negative SLNB result, about three will develop a recurrence in the same group of lymph nodes
The operation requires a general anaesthetic
The procedure results in complications such as deep venous thrombosis, seromas, or wound infections in 4-10 of every 100 people
Box 2: Possible advantages and disadvantages of completion lymphadenectomy
Advantages
Removing the rest of the lymph nodes before cancer develops in them reduces the chance of the cancer returning in the same part of the body
The operation is less complicated and safer than waiting until cancer develops in the remaining lymph nodes and then removing them
People who have had the operation may be able to take part in clinical trials of new treatments to prevent future melanoma. These trials often cannot accept people who have not had this operation
Disadvantages
Lymphoedema (long term swelling) may develop; it is more likely if the operation is in the groin and least likely in the head and neck
In four out of five people, cancer will not develop in the remaining lymph nodes, so there is a chance that the operation will have been done unnecessarily
There is no evidence that people who have this operation live longer than those who do not have it
Having any operation can cause complications
Managing stage IV melanoma (distant metastases)
Many patients with metastases will be treated with targeted therapy in line with NICE guidance on dabrafenib, ipilimumab and vemurafenib. 6-9 However, some situations require separate advice:
• 
Overcoming barriers
Dermoscopy is not routinely used in all clinics where pigmented lesions are assessed, so equipment will need to be purchased and staff trained. Vitamin D is rarely measured and there is uncertainty about how best to manage suboptimal levels. New guidance from the Scientific Advisory Committee on Nutrition (SACN) expected in 2015 will be helpful. Not all MDTs offer SLNB and some that do reportedly do not always offer the choice of not having it. Change is needed both in how this is discussed with patients and in its provision where it is currently unavailable.
Box 3: Possible advantages and disadvantages of follow-up imaging
Advantages
Early detection of recurrence may allow people to receive treatment with drugs such as immunotherapeutic agents earlier than they would otherwise, which might lead to better outcomes Some patients find it reassuring to have regular scans
Disadvantages
There is currently no evidence that treating recurrent melanoma earlier increases the probability of a better outcome
Having regular scans may increase some people's anxiety, even though for many, no recurrence will ever occur Regular scans increase the body's exposure to radiation, which itself increases the risk of second cancers later in life. For example, imaging of the chest results in a very small increase in the risk of thyroid cancer
Imaging of the brain and neck results in a small increase in the risk of developing cataracts
Incidental abnormalities of no clinical significance that require further investigations might be identified, and this may cause anxiety until the situation is resolved
Further information on the guidance
Methods
This guidance was developed by the National Collaborating Centre for Cancer using current NICE guideline methodology (www.nice.org. uk/guidelinesmanual). The guidance review process involved literature searches to identify relevant evidence, with critical appraisal of the quality of the identified evidence. A multidisciplinary team of service users, carers, and healthcare professionals (including dermatologists, surgeons, clinical and medical oncologists, a general practitioner, a histopathologist, a radiologist, clinical nurse specialists, and patient and carer representatives)-the guideline development group (GDG)-was established to review the evidence and develop the subsequent recommendations. The guidance then went through an external consultation with stakeholders. The GDG considered the stakeholders' comments, reanalysed the data where necessary, and modified the guidance as appropriate.
NICE has produced three different versions of the guidance: a full version; a summary version known as the "NICE guidance"; and a version for people using NHS services, their families, and carers (www.nice.org.uk/guidance/ng14/informationforpublic), and the public. All these versions are available from the NICE website (www.nice.org.uk/guidance/ng14). Further updates of the guidance will be produced as part of NICE's guideline development programme. Implementation tools are available at www.nice.org.uk/guidance/ng14/resources.
Future research
Based on its review of evidence, the GDG has made the following recommendations for research to improve NICE guidance and patient care in the future:
• In people with reported atypical spitzoid lesions, how effective are fluorescence in situ hybridization, comparative genomic hybridisation, and tests to detect driver mutations compared with histopathological examination alone in predicting disease specific survival?
• For people with lentigo maligna (stage 0 in sun damaged skin, usually on the face), how effective is Mohs micrographic surgery, compared with excision with a 0.5 cm clinical margin, in preventing biopsy confirmed local recurrence at five years?
• In people treated for high risk stages II and III melanoma, does regular surveillance imaging improve melanoma specific survival compared with routine clinical follow-up alone?
• In people with stages I-III melanoma, does vitamin D supplementation improve overall survival?
• In people diagnosed as having melanoma, what is the effect of drug therapy to treat concurrent conditions on disease specific survival?
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